Extended IASD Investigation: REDUCE LAP-HF IV

Heart Failure With Preserved Ejection Fraction Clinical Trial

Official title:

A Study to Evaluate the Corvia Medical, Inc. IASD® System II to REDUCE Elevated Left Atrial Pressure in Patients With Heart Failure

Clinical Trial Details — Status: Withdrawn

Administrative data

• NCT number: NCT04632160
• Other study ID #: 2001
• Status: Withdrawn
• Phase: N/A
• Start date: December 1, 2021
• Est. completion date: January 1, 2027

Study information

• Verified date: July 2021
• Source: Corvia Medical
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Multicenter, Prospective, Open Label, Single Arm, Clinical Trial. The primary objective of this clinical trial is to further evaluate the safety and clinical efficacy of the IASD System II in symptomatic heart failure patients with an left ventricular ejection fraction (LVEF) ≥ 40%, and elevated left sided filling pressures despite standard Guideline Directed Medical Therapy (GDMT); and to compare the safety and efficacy results to those from the treatment arm of the REDUCE LAP-HF Randomized Trial II (Corvia protocol 1601).

Description:

Participants are screened against non-invasive eligibility criteria and scheduled for a hemodynamic evaluation. Following right heart catheterization at rest and during supine bicycle exercise, patients will undergo a brief intracardiac echocardiography (ICE) or transesophageal echocardiography (TEE) exam for septal suitability. Eligible patients continue with, fluoroscopically and echo guided transseptal puncture and IASD System II implant procedure. If a previously unknown protocol exclusion is discovered during the index procedure, and device is not implanted, participant is followed for 30 days, and then exits the study. Participants return for follow-up exams 30 days after the implant procedure and annually for 5 years after the implant procedure. In-person visits will take place for the first 2 years. Telephone follow-up and medical chart review will be conducted for years 3-5.

Recruitment information / eligibility

• Status: Withdrawn
• Enrollment: 0
• Est. completion date: January 1, 2027
• Est. primary completion date: January 1, 2022
• Accepts healthy volunteers: No
• Gender: All
• Age group: 40 Years and older

Eligibility

Select Inclusion Criteria:

• Chronic symptomatic heart failure with preserved or mid-range left ventricular ejection fraction (HFpEF or HFrEF)
• Participant is willing to comply with clinical investigation procedures and agrees to return for all required follow-up visits, tests, and exams

Select Exclusion Criteria:

• Myocardial infarction and/or percutaneous cardiac intervention within past 3 months; Coronary artery bypass surgery in past 3 months, or current indication for coronary revascularization; AVR (surgical AVR or TAVR) within the past 12 months
• Advanced heart failure
• History of stroke, transient ischemic attack (TIA), deep vein thrombosis (DVT), or pulmonary emboli within the past 6 months
• Significant heart valve disease
• Chronic pulmonary disease
• Women of childbearing potential
• Severe obstructive sleep apnea not treated with CPAP or other measures

Related Conditions & MeSH terms

• Heart Failure
• Heart Failure With Mid Range Ejection Fraction
• Heart Failure With Preserved Ejection Fraction

Intervention

Device:
• IASD System II
The implant is placed across the interatrial septum using a percutaneous transcatheter approach.

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
Corvia Medical

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Incidence of and time-to-cardiovascular mortality or first non-fatal, ischemic stroke through 12 months		12 Month
Primary	Total rate (first plus recurrent) per patient year of heart failure (HF) admissions or healthcare facility visits for IV diuresis for HF up to 24 months, analyzed when the last subject completes 12 month follow-up, and time-to-first HF event		Up to 24 Months
Primary	Change in baseline Kansas City Cardiomyopathy Questionnaire (KCCQ) total summary score at 12 months		12 Month
Secondary	Cardiovascular mortality through 12 months		12 Months
Secondary	Non-fatal, ischemic stroke through 12 months		12 Months
Secondary	New onset or worsening of kidney dysfunction (defined as eGFR decrease of > 20 ml/min/1.73 m2) through 12 months		12 Months
Secondary	Incidence of Major Cardiac Events i. Cardiac death ii. Myocardial infarction iii. Cardiac tamponade iv. Emergency cardiac surgery.		12 Months
Secondary	Thrombo-embolic complications (TIA, systemic embolization) through 12 months		12 Months
Secondary	=30% increase in right ventricular size/decrease in TAPSE through 12 months		12 Months
Secondary	Newly acquired persistent or permanent AF or atrial flutter through 12 months		12 Months
Secondary	Total rate per patient year of heart failure admissions or healthcare facility visits for IV diuresis or visits with intensification of oral diuresis for HF through 24 months, analyzed when the last subject completes 12 months follow-up		Up to 24 months
Secondary	Change in New York Heart Association (NYHA) functional Class between baseline and 12 months		12 Months
Secondary	Change in Kansas City Cardiomyopathy Questionnaire (KCCQ) score between baseline and 12 months, categorized as =0, >0 - 5, >5 - 10, >10 - 15, >15 - 20, >20 - 25, >25.		12 Months